Cargando…

The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma

Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Shi, Yuanfei, Shen, Huafei, Shou, Lihong, Fang, Qiu, Zheng, Xiaolong, Zhu, Mingyu, Huang, Xin, Huang, Jiansong, Li, Li, Zhou, De, Zhu, Lixia, Zhu, Jingjing, Ye, Xiujin, Jin, Jie, Xie, Wanzhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555175/
https://www.ncbi.nlm.nih.gov/pubmed/34715862
http://dx.doi.org/10.1186/s12935-021-02275-2
_version_ 1784591924178452480
author Zhang, Yan
Shi, Yuanfei
Shen, Huafei
Shou, Lihong
Fang, Qiu
Zheng, Xiaolong
Zhu, Mingyu
Huang, Xin
Huang, Jiansong
Li, Li
Zhou, De
Zhu, Lixia
Zhu, Jingjing
Ye, Xiujin
Jin, Jie
Xie, Wanzhuo
author_facet Zhang, Yan
Shi, Yuanfei
Shen, Huafei
Shou, Lihong
Fang, Qiu
Zheng, Xiaolong
Zhu, Mingyu
Huang, Xin
Huang, Jiansong
Li, Li
Zhou, De
Zhu, Lixia
Zhu, Jingjing
Ye, Xiujin
Jin, Jie
Xie, Wanzhuo
author_sort Zhang, Yan
collection PubMed
description Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL have been established in retrospective studies, some high-risk patients still can not be screened out. Therefor we retrospectively studied 347 newly diagnosed PTCL patients and assessed the prognostic role of lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) in the complete response (CR) and survival of PTCL patients. Patients with LMR ≤ 1.68 and PMR ≤ 300 achieved a lower CR rate and a poor survival. In multivariate analysis, LMR ≤ 1.68 (HR = 1.751, 95% CI 1.158–2.647, p < 0.05) and PMR ≤ 300 (HR = 1.762, 95% CI 1.201–2.586, p < 0.05) were independently associated with short survival. On this basis, a new prognostic model of PTCL was established to screen out high-risk patients. In our "Peripheral Blood Score (PBS)" model, three groups were identified at low risk (178 patients, 51.3%, score 0), intermediate risk (85 patients, 24.5%, score 1), and high risk (84 patients, 24.2%, score 2), having a 1-year OS of 86%, 55.3% and 22.6% (p < 0.05), and a 3-year OS of 43.4%, 20% and 13.1% (p < 0.05), respectively. Optimal strategies for identifying high-risk patients with PTCL are urgently needed. Our new PBS model is simple, inexpensive and widely available to screen out the high risk patients.
format Online
Article
Text
id pubmed-8555175
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85551752021-10-29 The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma Zhang, Yan Shi, Yuanfei Shen, Huafei Shou, Lihong Fang, Qiu Zheng, Xiaolong Zhu, Mingyu Huang, Xin Huang, Jiansong Li, Li Zhou, De Zhu, Lixia Zhu, Jingjing Ye, Xiujin Jin, Jie Xie, Wanzhuo Cancer Cell Int Primary Research Peripheral T-cell lymphoma(PTCL) is a group of lymphoproliferative tumors originated from post-thymic T cells or mature natural killer (NK) cells. It shows highly aggressive clinical behaviour, resistance to conventional chemotherapy, and a poor prognosis. Although a few prognostic models of PTCL have been established in retrospective studies, some high-risk patients still can not be screened out. Therefor we retrospectively studied 347 newly diagnosed PTCL patients and assessed the prognostic role of lymphocyte-monocyte ratio (LMR) and platelet-monocyte ratio (PMR) in the complete response (CR) and survival of PTCL patients. Patients with LMR ≤ 1.68 and PMR ≤ 300 achieved a lower CR rate and a poor survival. In multivariate analysis, LMR ≤ 1.68 (HR = 1.751, 95% CI 1.158–2.647, p < 0.05) and PMR ≤ 300 (HR = 1.762, 95% CI 1.201–2.586, p < 0.05) were independently associated with short survival. On this basis, a new prognostic model of PTCL was established to screen out high-risk patients. In our "Peripheral Blood Score (PBS)" model, three groups were identified at low risk (178 patients, 51.3%, score 0), intermediate risk (85 patients, 24.5%, score 1), and high risk (84 patients, 24.2%, score 2), having a 1-year OS of 86%, 55.3% and 22.6% (p < 0.05), and a 3-year OS of 43.4%, 20% and 13.1% (p < 0.05), respectively. Optimal strategies for identifying high-risk patients with PTCL are urgently needed. Our new PBS model is simple, inexpensive and widely available to screen out the high risk patients. BioMed Central 2021-10-29 /pmc/articles/PMC8555175/ /pubmed/34715862 http://dx.doi.org/10.1186/s12935-021-02275-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Zhang, Yan
Shi, Yuanfei
Shen, Huafei
Shou, Lihong
Fang, Qiu
Zheng, Xiaolong
Zhu, Mingyu
Huang, Xin
Huang, Jiansong
Li, Li
Zhou, De
Zhu, Lixia
Zhu, Jingjing
Ye, Xiujin
Jin, Jie
Xie, Wanzhuo
The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma
title The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma
title_full The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma
title_fullStr The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma
title_full_unstemmed The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma
title_short The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma
title_sort value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral t-cell lymphoma
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555175/
https://www.ncbi.nlm.nih.gov/pubmed/34715862
http://dx.doi.org/10.1186/s12935-021-02275-2
work_keys_str_mv AT zhangyan thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT shiyuanfei thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT shenhuafei thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT shoulihong thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT fangqiu thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhengxiaolong thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhumingyu thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT huangxin thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT huangjiansong thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT lili thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhoude thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhulixia thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhujingjing thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT yexiujin thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT jinjie thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT xiewanzhuo thevalueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhangyan valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT shiyuanfei valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT shenhuafei valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT shoulihong valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT fangqiu valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhengxiaolong valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhumingyu valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT huangxin valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT huangjiansong valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT lili valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhoude valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhulixia valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT zhujingjing valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT yexiujin valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT jinjie valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma
AT xiewanzhuo valueofanewprognosticmodeldevelopedbylymphocytemonocyteratioandplateletmonocyteratioinperipheraltcelllymphoma